iPETcertum

iPETcertum is a German biotechnology company specializing in the development and commercialization of novel radiopharmaceuticals for molecular imaging and targeted therapy. A spin-off from the University of Tübingen, the company focuses on Positron Emission Tomography (PET) tracers that target specific biomarkers in the tumor microenvironment, such as Fibroblast Activation Protein (FAP). Their lead programs include diagnostic and therapeutic ligands designed to improve the detection and treatment of various solid tumors, including prostate and breast cancers. By integrating advanced imaging with precision medicine, iPETcertum provides theranostic solutions to clinical and pharmaceutical partners. The company operates out of Tübingen, leveraging close ties to academic research centers to accelerate its pipeline.